Company news

TheraCryf PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Change of Name

April 25, 2024

Result of Retail Offer

April 4, 2024

Retail Offer

March 19, 2024

SFX-01 positive update in bowel cancer models

February 27, 2024

Positive update on SFX-01 in vitro GBM studies

February 19, 2024

Notice of Dispute lodged with Stalicla SA

February 9, 2024

Series B Fund Raise by partner, Stalicla SA

January 16, 2024

Directorate Changes

December 22, 2023

Upcoming conferences

November 13, 2023

Erasmus Medical Center begins glioblastoma studies

October 26, 2023

Authored Article Publication

October 19, 2023

Final Report from Phase 1b PK/PD study

August 15, 2023

Rule 17 Disclosure

August 3, 2023

Return of rights to Sulforadex from Juvenescence

August 2, 2023

SFX-01 radiosensitisation effect confirmed in-vivo

June 27, 2023

Notice of AGM & Posting of Annual Report

June 20, 2023

Grant Success for Glioblastoma studies

June 19, 2023

Final Results

June 7, 2023

Distribution Dates and Amounts Announced for...

May 1, 2023

Preliminary results from Phase 1b study

March 22, 2023

Price Monitoring Extension

March 16, 2023

No exposure to Silicon Valley Bank

March 13, 2023

Clinical trial update

January 25, 2023

Grant of Options - Director/PDMR Shareholding

December 14, 2022

Evgen Pharma 'cash runway in pretty good shape'

December 12, 2022

Notice of Half Year Results

December 2, 2022

Second Price Monitoring Extn

November 30, 2022

Study started of new SFX-01 tablet formulation

November 16, 2022

SFX-01 licensing deal for up to $160.5m

October 10, 2022

Regulatory approval for healthy volunteer study

September 29, 2022

Investor Presentation

July 14, 2022

Collaboration with University of Michigan

June 13, 2022

Full Year Results

June 8, 2022

Collaboration with Università Sapienza di Roma

May 25, 2022

Manchester Breast Centre collaboration expanded

March 7, 2022

Option over new sulforaphane analogues

January 18, 2022

Progress with UK and US regulators for 2022 trials

January 11, 2022

Grant of Options

December 8, 2021

Publication of data on SFX-01 in glioblastoma

November 10, 2021

Publication of data in glioblastoma cells

September 20, 2021

Glioma Orphan Drug designation granted by FDA

September 2, 2021

Result of AGM and Business Update

July 13, 2021

Interim Safety and Futility Analysis - STAR trial

July 9, 2021

Posting of Annual Report and Notice of AGM

June 18, 2021

Progress with Glioma/Glioblastoma programme

June 14, 2021

Appointment of Chief Medical Officer

April 26, 2021

Publication on sulforaphane in COVID-19

April 7, 2021

Appointment of Chief Business Officer

March 22, 2021

Update on Data Safety Review - STAR COVID-19 trial

March 11, 2021

Director dealing

March 5, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 12 calls. Every call is listed under its year.

Decks

The 5 newest of 15 decks. Every deck is listed under its year.